Mount Carmel Health Partners HEDIS Tip Sheets - Page 3

Table Table of of Contents Contents Annual Monitoring for Patients on Persistent Medications: Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers (ARBs)............................... 4 Annual Monitoring for (ACE) Patients on Persistent Medications: Angiotensin Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARBs) . . . . . . 3 Annual Monitoring for Patients on Persistent Medications: Digoxin...................................................................... 6 Annual Monitoring for on Patients on Persistent Medications: Digoxin . . . . . . . . . . . . . . . . 4 Annual Monitoring for Patients Persistent Medications: Diuretics................................................................... 7 Monitoring for Patients on Persistent Medications: Diuretics . . . . . . . . . . . . . . . 5 Body Mass Annual Index.................................................................................................................................................... 9 Breast Cancer ...................................................................................................................................... 11 Body Screening. Mass Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Cervical Cancer 12 Breast Screening.................................................................................................................................... Cancer Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Chlamydia Screening in Women........................................................................................................................... 13 Cervical Cancer Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Colorectal Cancer Screening................................................................................................................................. 14 Chlamydia Screening in Women . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Controlling Blood Pressure................................................................................................................................... 16 Colorectal Cancer Screening . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Diabetes – Dilated Eye Exam................................................................................................................................ 17 Controlling Blood Pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Diabetes – HbA1c Control.................................................................................................................................... 19 Diabetes – Dilated Eye Exam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Diabetes – Medical Attention for Nephropathy................................................................................................... 20 – HbA1c Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Diabetes – Diabetes Statin Therapy.................................................................................................................................... 22 Diabetes Anti‐Rheumatic – Medical Attention Nephropathy . . . Arthritis............................................................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Disease Modifying Drug for (DMARD) Therapy . . for 23 Medication Reconciliation Discharge. 25 Diabetes – Statin Post Therapy . . . . . . .......................................................................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Medication Adherence for Cholesterol................................................................................................................ 26 Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Arthritis . . . . . . . . . . . . . 17 Medication Adherence for Diabetes.................................................................................................................... 27 Medication Reconciliation Post Discharge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Medication Adherence for Hypertension............................................................................................................. 28 Medication Adherence for Cholesterol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Osteoporosis Management in Women Who Have Had a Fracture....................................................................... 30 Medication Adherence for Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Transitions of Care (TRC)...................................................................................................................................... 32 Medication Adherence for Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Osteoporosis Management in Women Who Have Had a Fracture . . . . . . . . . . . . . . . . . . . 23 Transitions of Care (TRC) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 24